

CANCER FUND I

**SPECIAL PURPOSE VEHICLE:
CF1 REGLAGENE PARTNERS, LLC**

An Impact Investment Targeting Brain Cancers

Reglagene – pioneering an oral medication for the treatment of glioblastoma and metastatic brain cancers. CANCER FUND I is leading their \$5MM Series A-1 financing and inviting others to invest with us

About CANCER FUND I

CANCER FUND I is an early-stage venture fund investing in therapies, diagnostics, and other innovations with the potential to improve outcomes, increase access to care, and reduce the cost of care for cancer patients, survivors, and at-risk individuals. CANCER FUND I invested in Reglagene's previous Seed round and is excited to lead this Series A-1 round.

Our Target Investment: Reglagene



Overview

- Reglagene efficiently develops new medicines that safely and effectively penetrate the blood-brain barrier to treat deadly brain cancers
- Reglagene's orally administered medicine offers greater patient convenience, efficacy, and safety for patients afflicted with difficult-to-treat brain cancers

\$7B Market Opportunity

\$720MM

High Grade Glioma,
including glioblastoma
(Beachhead)

\$6.4Bn

Breast, Lung,
Melanoma with brain
metastases

Milestones and Timeline

2022

Select Clinical
Candidate

2023

FDA IND Filing

Why CANCER FUND I Is Investing

Superior Blood Brain Barrier Penetration:

The human brain has a barrier membrane that filters out toxins and medicines. For the first time, a broad variety of brain cancers can be targeted with an effective therapy owing to Reglagene's excellent brain penetration

Outstanding Safety Profile:

Multi-week studies in animals have been completed without weight loss, organ toxicity, or abnormal neurological behaviors

Relative Affordability:

Reglagene's orally administered medicine benefits from low manufacturing costs to offer a cost-effective therapy that increases patient access.

Orally Administered:

Reglagene's orally administered medicines support lower dosage rates than IV administered medications for better management and tolerability.

An Extendable Therapy Platform:

Reglagene's oral medicine platform has the potential to treat other cancers and diseases beyond its initial target of glioblastoma and metastatic brain cancer

An Exceptional Management Team with Successful Track Record:

Management team and advisors have moved 37 medicines from the laboratory bench to clinical trials

For More Information

Anthony Bajoras
Managing Director
CANCER FUND
anthony@cancerfund.com
t: 602-821-1500

CANCER FUND 4144 North 44th Street, Suite 3, Phoenix, AZ 85018. The confidential information contained herein has been prepared solely for information purposes on behalf of CF1 Reglagene Partners, LLC ("SPV" or the "Company"). The recipient agrees to be responsible for any unauthorized disclosure of the information contained herein by it or its advisors or representatives. Under no circumstances should any of the Company's management, employees, principals, customers or suppliers be contacted in relation to this possible transaction. No representation, warranty or undertaking, expressed or implied, is or will be made, and no responsibility or liability will be accepted, by CANCER FUND, CANCER FUND I, LLC, CF1 Reglagene Partners, LLC or the Company, or any of their respective affiliates, associates, directors, officers, employees, agents, advisors or shareholders, as to, or in relation to, the accuracy or completeness of the information contained herein, or any other information, errors therein or omissions therefrom. Projections are based on Company estimates as of May 2022. CANCER FUND has not independently verified any of such information and assume no responsibility for its accuracy or completeness.